In February 2017, MAPS received $93,000 in new donations and pledges from 250 supporters. The new year marked our final negotiations with the U.S. Food and Drug Administration (FDA) as we move onto our final Phase 3 trials of MDMA-assisted psychotherapy for PTSD. We are still on track to make MDMA a medicine by 2021, and in the coming years our funding needs will grow substantially. Our Phase 3 trials will cost at least $25 million. With $10 million in hand, there’s still a funding gap we need to close.
We extend a special thanks to those who generously supported MAPS this past month:
General Support
- John Gilmore ($30,000)
- Mai Family Foundation ($25,000)
- AmazonSmile Foundation ($1,564)
- Benjamin Marinoff ($1,000)
GMP MDMA for MDMA/PTSD Phase 3
- Anonymous ($10,000)
- Bonnie Brunet and Martin Rist ($1,000)
- Greg Logan ($1,000)
MDMA/PTSD Phase 3 Studies
- Peter Glynn ($5,000)
- Steven Weinstein and Marcia Meislin ($1,000)
Zendo Project
- David Bronner ($5,850)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations. Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate
